KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...

A phase 1/2 trial of CRISPR-engineered eTIL therapy KSQ-004EX for advanced solid tumors has dosed its first patient.

Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.

SOCS1 is “a critical regulator of cytokine signaling,” per the study authors, and reduced levels of it are associated with ...